www.fdanews.com/articles/122905-dynavax-8217-s-european-manufacturing-facility-approved-for-heplisav
Dynavax’s European Manufacturing Facility Approved for Heplisav
December 11, 2009
Dynavax Technologies Corporation announced that its GMP manufacturing
facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV, the Company’s
investigational adult hepatitis B vaccine.
CNNMoney
CNNMoney